RISK FACTORS FOR DEVELOPMENT OF UNFAVORABLE PERINATAL OUTCOMES AND EFFECT OF DRUGS ADMINISTERED TO PREGNANT WOMEN

Abstract


Aim. To reveal the most significant factors influencing development of unfavorable perinatal outcomes and to assess the efficiency of drugs administered to pregnant women for their prevention. Materials and methods. On the basis of retrospective analysis of medical documents belonging to 34 women with physiological and 255 patients with complicated course of gestation, risk factors for development of unfavorable fetal and newborn outcomes (perinatal mortality, congenital malformation and hypoxia at birth) and effect of drugs administered to pregnant women were analyzed. Results. Among the factors increasing the risk for development of unfavorable fetal and newborn gestation outcomes, the most significant and early detected ones were chronic somatic, gynecological as well infectious and inflammatory diseases revealed during pregnancy. Out of traditionally administered to pregnant women drugs, the most evident positive effect on perinatal outcomes was connected with use of drugs for vaginal sanation, immunomodulators, disaggregants and actovegin (pyracetam). Early administration of any drugs permitted in pregnancy notably decreased the risk for newborn perinatal mortality and hypoxia. Conclusions. Among the examined patients, the most significant and early detected risk factors for development of unfavorable fetal and newborn outcomes are chronic infectious-inflammatory diseases diagnosed before and during pregnancy. Decrease in risk for unfavorable perinatal outcomes is connected with administration of drugs for vaginal sanation, immunomodulators, disaggregants and activegin (pyracetam) as well as early onset of therapeutic and preventive measures.

About the authors

V V Skryabina

Email: skryabina-vv@mail.ru

References

  1. Акушерство: справочник Калифорнийского университета: пер. с англ. / под ред. К. Нисвандера и А. Эванса. М.: Практика 1999; 468.
  2. Инфекции в акушерстве и гинекологии / под редакцией О. В. Макарова, В. А. Алешкина, Т. Н. Савченко. М.: МЕДпресс-информ 2009; 464.
  3. Кальф-Калиф Я. Я. О лейкоцитарном индексе интоксикации и его практическом значении. Врачебное дело 1941; 1: 31-35.
  4. Радзинский В. Е., Князев С. А., Костин И. Н. Акушерский риск. Максимум информации - минимум опасности для матери и младенца. М.: Эксмо 2009; 288.
  5. Сидельникова В. М., Сухих Г. Т. Невынашивание беременности: руководство для практикующих врачей. М.: Медицинское информационное агентство 2010; 536.
  6. Фролова О. Г., Шувалова М. П., Гребенник Т. К., Долгушина Н. В. Перинатальная смертность в Российской Федерации. Возможные пути ее снижения. Акушерство и гинекология 2012; 6: 47-51.
  7. Blencowe H., Cousens S., Modell B., Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. J. Epidemiol. 2010; 39: 110-121.
  8. Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks’ gestation: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2009; 200: 595-609.
  9. Dodd J. M., Jones L., Flenady V., Cincotta R., Crowther C. A. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane. Database. Syst. Rev. 2013; Jul: 31; 7: CD004947. DOI: 10.1002 / 14651858.CD004947. pub3. 2013.
  10. Feldkamp M. L. Case-control study of self reported genitourinary infections and risk of gastroschisis: findings from the national birth defects prevention study. BMJ 2008; 336; 1420-1423.
  11. Fonseca E. B. Progesterone and the risk of preterm birth among women with a short cervix. N. Engl. J. Med. 2007; 357: 462-469.
  12. Ionescu-Ittu R., Marelli A. J., Mackie A. S. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ 2009; 338; b1673.
  13. Lumbiganon P. Multiple-micronutrient supplementation for women during pregnancy: RHL commentary (last revised: 23 August 2007). The WHO Reproductive Health Library. Geneva: World Health Organization 2007.
  14. Spatling L., Spatling G. Magnesium supplementation in pregnancy. A double-blind study. Br. J. Obstet. Gynaecol. 1988; 2: 120-125.
  15. Swadpanich U., Lumbiganon P., Prasertcharoensook W., Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database of Systematic Reviews 2008; 2 (CD006178. doi: 10.1002/14651858.CD006178.pub2).
  16. The Supplementation with Multiple Micronutrients Intervention Trial (SUMMIT) Study Group, Shankar A. H. et al. Effect of maternal multiple micronutrient supplementation on fetal loss and infant death in Indonesia: a double-blind cluster-randomised trial. Lancet 2008; 371: 215-227.

Statistics

Views

Abstract - 260

PDF (Russian) - 158

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2014 Skryabina V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies